Dr Chouaib completed his undergraduate studies at the university of Pierre and Marie Curie (Paris VI) at Pasteur Institute. He received his Doctorates-sciences (Ph.D.) in immunology, (laboratory of Jean Dausset, Nobel prize in medicine) in 1983 from the same university. He then joined the Memorial Sloan Kettering Cancer Center in New York where he undertook a post-doctoral training in Human Immunogenetics Laboratory. In 1986, he was appointed as research associate at the French National Institute of Health and Biomedical Research (INSERM) and joined the tumor biology department at the InstitutGustaveRoussy. At present he is the Research Director (exceptional class) and is heading the INSERM research unit 753 (Human Cancer Immunology and Immunotherapy).

His laboratory currently focuses on the investigation of the functional cross talk between cytotoxic cells and tumor targets in the context of tumor microenvironment complexity and plasticity. His research was constantly directed at impulsing the transfer of fundamental concepts in clinical application in particular in the field of cancer vaccine and cancer immunotherapy. Besides his research activity, he has a very strong educational mission as he founded 2 doctoral schools.

Dr Chouaib'smajor teaching responsibilities include: Faculty member of Immunology (Necker Hospital, Saint-Louis Hospital, Kremlin Bicêtre Faculty of Medicine) and Course Directory, Immunology Program, GustaveRoussy, (Ecoledoctorale de cancérologie, Villejuif). He is a member of the American Association of Immunologists, New York Academy of Sciences, French Society of Immunologists, International Cytokine Society, American Association for Cancer Research, International Society for Biological Therapy of Cancer and American Association of Biological Chemistry. He gives lectures in tumor immunology and immunotherapy for several PhD programs at different universities in France and abroad. He was awarded the cancer research prize of the French ligue against cancer in 1992 and in 2004 the presidential prize in biotechnology.

Dr Chouaib'sresearch resulted in more than 300 scientific articles and several reviews in the field of human immunology and tumor biology as well as in editorship for contribution to several books. Furthermore he is guest lecturer at different universities. He is a member of various professional associations and scientific advisor and consultant in many scientific institutions.

Over the past few years he has served as scientific advisor to General Directors of GustaveRoussy Institute and the French National Institute for health and biomedical research (INSERM). His Consultancies and Industrial Experience include: Scientific consultant at RusselUclaf (Romainville-France); Scientific advisor to the Vice President of Research and Development. Vertex UK; Scientific consultant (Cryobank, California: Scientific advisor for the development of cord blood cells in cell therapy; Advisor to the general Director of Health and Biomedical research (INSERM) for the Gulf Countries; Expert European Union 2006-present; Consultant GenticellPharma 2008-present; Consultant PharnextPharma: 2011-present; Consultant Vaxon Biotech: 2013-present.

Dr Chouaib has extensive Administrative Experience in different capacities as member of the immunology section committee (National Institute for Health and Medical Research, INSERM, France); Member of the Scientific Advisory committee of the French Ligue against Cancer; Member of Scientific Council, GustaveRoussy, Villejuif; Member of the Scientific Advisory committee of the French Ligue against Cancer; Member of the Scientific Advisory committee of the Research Association against Cancer(ARC); Member of the Scientific Council of the French National Cancer Plan; Member of the AFSAPS (French food and drug administration); Member of the Council "Studium of Molecular Medicine" International Doctorate School; Member of the

International Council, Pasteur Institute (Tunisia); Member of Academy of sciences, letters and arts (Tunisia); Member of the Education Task Force of Cancer Core, Europe.